引用次数
引用: 63,129
H-指数: 101
I10-指数 : 366
出版物: 915
PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
A. Bearz , O. Caffo , A. Follador , R. Chiari
Journal of Thoracic Oncology 16 ( 3)
2021
Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma
G. Scagliotti , D. Shin , H. Kindler , D. Johnson
European Journal of Cancer 37
23
2001
Phase II trial of BBR3464, a novel, bifunctional platinum analog, in advanced but favorable out-come, Non Small Cell Lung Cancer patients
G. Scagliotti , L. Crinò , F. De Marinis , M. Tonato
European Journal of Cancer 37
3
2001
Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer
G. Scagliotti , V. Monica , P. Ceppi , L. Righi
Journal of Clinical Oncology 27 7521 -7521
17
2009
Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial
S. Novello , L. E. Abrey , F. Grossi , C. Camps
Journal of Clinical Oncology 27 ( 15_suppl) 8077 -8077
4
2009
Impact of early lung cancer detection on surgical mortality
U. Pastorino , P. Borasio , P. Solli , M. Bellomi
Journal of Clinical Oncology 22 7047 -7047
1
2004
Phase 3 Study (MONET1) of Motesanib Plus Carboplatin/Paclitaxel (C/P) in Patients with Advanced NSCLC: Asian Subgroup Analysis
K. Park , Y. Ichinose , G. Scagliotti , D. Spigel
Annals of Oncology 23
2012
Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer.
J. K. Blayney , C. M. Grills , P. V. Jithesh , I. I. Wistuba
Journal of Clinical Oncology 28 1599 -1599
2010
Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
G. Allegrini , P.F. Conte , F. Salvati , F. Nunziati
Annals of Oncology 8 ( 6) 561 -567
21
1997
6521 POSTER Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)
P. Peterson , K. Park , F. Fossella , U. Gatzemeier
Ejc Supplements 5 ( 4) 363 -364
31
2007
6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
G. Scagliotti , K. Park , S. Patil , J. Rolski
Ejc Supplements 5 ( 4) 363
2
2007
O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data
T. Le Chevalier , A. Brown , R. Natale , G. Scagliotti
Lung Cancer 41
13
2003
141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials.
E. Felip , L. Crinò , D.-W. Kim , D.R. Spigel
Journal of Thoracic Oncology 11 ( 4)
12
2016
Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC)
G. Scagliotti , A. Rossi , S. Novello , F. De Marinis
Journal of Clinical Oncology 22 7081 -7081
22
2004
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
K. Kubota , Y. Ichinose , G. Scagliotti , D. Spigel
Annals of Oncology 25 ( 2) 529 -536
19
2014
Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: A case-control study and prevalence data
G. Scagliotti , T. Kalebic , M. Volante , S. Cappia
Journal of Clinical Oncology 24 7049 -7049
2006
European School of Oncology First Euro-American Forum on Lung Cancer Treatment
P.A. Bunn , N. Van Zandwijk , U. Pastorino , J. Aisner
European Journal of Cancer 30 ( 5) 710 -713
16
1994
Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018.
P. Lombardi , L. Marandino , E. De Luca , C. Zichi
Annals of Oncology 30
2
2019
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients
J.D. Patel , J.R. Pereira , J. Chen , J. Liu
Annals of Oncology 27 ( 8) 1612 -1619
15
2016
P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma
R. Taulli , L. Righi , F. Tabbò , F. Massa
Journal of Thoracic Oncology 13 ( 10)
2018